NCT06771609View on ClinicalTrials.gov

Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

September 10, 2028

Study Completion Date

September 10, 2028

Conditions
Advanced Triple-negative Breast Cancer
Interventions
DRUG

Adebry single antibody + VEX metronomic chemotherapy + radiotherapy

1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W

DRUG

debry single antibody + VEX metronomic chemotherapy

1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W

Trial Locations (2)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER